SCHEMBL3023540

SCHEMBL3023540

Cc1cc(C)cc(Cc2csc(N3CCN(S(=O)(=O)c4cccc(Br)c4)CC3)n2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
GBA1 P04062 3/20 0.44
USP2 O75604 4/20 0.41
MAPT P10636 3/20 0.41
HSD17B10 Q99714 2/20 0.41
RECQL P46063 1/20 0.41
CYP3A4 P08684 1/20 0.40
GRM5 P41594 1/20 0.40
MBTD1 Q05BQ5 1/20 0.40
L3MBTL3 Q96JM7 1/20 0.40
ALDH1A1 P00352 3/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
LMNA P02545 3/20 0.39
MAPK1 P28482 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TDP1 Q9NUW8 1/20 0.38
GPR183 P32249 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3007579 0.93 MEN1 (0.46) KMT2AMEN1GBA1USP2MAPT
SCHEMBL3011994 0.92 MEN1 (0.44) KMT2AMEN1GBA1USP2MAPT
SCHEMBL3012672 0.90 KMT2A (0.50) KMT2AMEN1GBA1USP2MAPT
SCHEMBL3010900 0.90 GBA1 (0.43) KMT2AMEN1GBA1USP2MAPT
SCHEMBL3009893 0.89 KMT2A (0.54) KMT2AMEN1GBA1USP2MAPT
SCHEMBL3013298 0.89 SMN1; SMN2 (0.46) KMT2AMEN1GBA1USP2MAPT
SCHEMBL3011321 0.89 MEN1 (0.43) KMT2AMEN1GBA1USP2MAPT
SCHEMBL3004373 0.89 KMT2A (0.44) KMT2AMEN1GBA1USP2MAPT
SCHEMBL3006492 0.89 SMN1; SMN2 (0.46) KMT2AMEN1GBA1USP2MAPT
SCHEMBL3016324 0.89 MAPT (0.47) KMT2AMEN1GBA1USP2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA KMT2A 2680/4885MEN1 454/4885GBA1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.